Medicare Enrolled
Dr. Ashish Dalal, MD
Hematology · Melbourne, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Dalal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dalal? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Dalal
Dr. Ashish Dalal is a hematology in Melbourne, FL, with 20 years in practice. Based on federal Medicare data, Dr. Dalal performed 232,779 Medicare services across 3,875 unique beneficiaries.
Between the years covered by Open Payments, Dr. Dalal received a total of $9,327 from 65 pharmaceutical and/or device companies across 556 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Dalal is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 15% volume in FL$ $9,327 industry payments
Medicare Practice Summary
Medicare Utilization ↗232,779
Medicare services
Top 15% in FL for hematology
3,875
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~11,639 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) | 39,750 | $1 | $3 |
| Pembrolizumab injection (Keytruda) | 31,600 | $41 | $106 |
| Iron infusion (Feraheme) | 26,010 | $0 | $3 |
| Azacitidine chemotherapy injection | 17,070 | $0 | $3 |
| Nivolumab injection (Opdivo) | 17,060 | $24 | $60 |
| Iron sucrose injection (Venofer) | 14,900 | $0 | $1 |
| Tocilizumab injection (Actemra) | 13,680 | $4 | $12 |
| Filgrastim injection (Zarxio) for white blood cells | 12,240 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) | 11,550 | $0 | $3 |
| Epoetin alfa injection (Retacrit) for anemia | 11,294 | $6 | $22 |
| Denosumab injection (Prolia/Xgeva) | 9,660 | $18 | $45 |
| Immune globulin infusion (Gammagard) | 9,560 | $36 | $90 |
| Injection, bendamustine hcl (bendeka), 1 mg | 4,526 | $13 | $44 |
| Dexamethasone injection (steroid) | 2,502 | $0 | $0 |
| Office visit, established patient (30-39 min) | 1,476 | $96 | $255 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,300 | $1 | $25 |
| Office visit, established patient (20-29 min) | 1,026 | $63 | $180 |
| Drug injection, under skin or into muscle | 718 | $10 | $42 |
| Anti-nausea injection (ondansetron/Zofran) | 628 | $0 | $1 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 610 | $21 | $57 |
| Injection, leucovorin calcium, per 50 mg | 607 | $3 | $8 |
| Administration of chemotherapy into vein, 1 hour or less | 602 | $96 | $256 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 426 | $48 | $133 |
| Injection, fluorouracil, 500 mg | 396 | $2 | $6 |
| Office visit, established patient, complex (40-54 min) | 355 | $135 | $358 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 331 | $55 | $143 |
| Injection of additional new drug or substance into vein | 297 | $12 | $36 |
| Injection, diphenhydramine hcl, up to 50 mg | 285 | $1 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 237 | $16 | $40 |
| New patient office visit (45-59 min) | 208 | $119 | $335 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 204 | $25 | $66 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 178 | $133 | $1,069 |
| Administration of chemotherapy into vein, each additional hour | 172 | $21 | $56 |
| Administration of additional new drug or substance into vein, 1 hour or less | 137 | $49 | $126 |
| Irrigation of implanted venous access drug delivery device | 112 | $17 | $50 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 107 | $1 | $5 |
| Red blood cells, leukocytes reduced, each unit | 93 | $46 | $564 |
| Collection of blood sample from implanted device | 79 | $19 | $52 |
| Initial hospital admission, moderate complexity | 79 | $102 | $265 |
| Injection, zoledronic acid, 1 mg | 76 | $6 | $36 |
| Transfusion of blood or blood products | 70 | $30 | $76 |
| Infusion, normal saline solution , 1000 cc | 70 | $2 | $6 |
| Infusion into a vein for hydration, 31-60 minutes | 60 | $23 | $95 |
| Hospital follow-up visit, moderate complexity | 60 | $62 | $156 |
| New patient office visit, complex (60-74 min) | 57 | $164 | $443 |
| Drawing of blood for a medical problem | 50 | $69 | $189 |
| Hospital follow-up visit, high complexity | 46 | $94 | $232 |
| Administration of additional new drug or substance into vein using push technique | 41 | $42 | $110 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 41 | $128 | $317 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 38 | $248 | $692 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 33 | $4 | $12 |
| Infusion into a vein for hydration, each additional hour | 24 | $9 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 21 | $14 | $40 |
| Injection of drug or substance into vein | 15 | $28 | $91 |
| Initial hospital admission, high complexity | 12 | $137 | $351 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
33.0% high complexity
65.2% medium
1.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,327
Total received (2018-2024)
Avg $1,332/year across 7 years
Top 44% in FL for hematology
65
Companies
556
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,167 (87.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,160 (12.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$67
2023$133
2022$1,355
2021$2,140
2020$1,433
2019$1,962
2018$2,236
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,025
PFIZER INC.
$772
Janssen Biotech, Inc.
$733
Amgen Inc.
$713
Celgene Corporation
$636
Seagen Inc.
$615
AstraZeneca Pharmaceuticals LP
$557
E.R. Squibb & Sons, L.L.C.
$386
Merck Sharp & Dohme Corporation
$378
Daiichi Sankyo Inc.
$312
Incyte Corporation
$286
GENZYME CORPORATION
$250
Genentech USA, Inc.
$199
Boehringer Ingelheim Pharmaceuticals, Inc.
$158
Bayer HealthCare Pharmaceuticals Inc.
$149
Octapharma USA, Inc.
$146
Seattle Genetics, Inc.
$146
Regeneron Healthcare Solutions, Inc.
$109
GlaxoSmithKline, LLC.
$100
TESARO, Inc.
$97
Astellas Pharma US Inc
$94
Lilly USA, LLC
$87
Pharmacyclics LLC, An AbbVie Company
$84
Global Blood Therapeutics, Inc.
$83
PUMA BIOTECHNOLOGY, INC.
$74
Janssen Pharmaceuticals, Inc
$69
Foundation Medicine, Inc.
$67
MorphoSys, US Inc.
$57
Sun Pharmaceutical Industries Inc.
$57
Karyopharm Therapeutics Inc.
$56
Taiho Oncology, Inc.
$50
Myovant Sciences Inc.
$50
JAZZ PHARMACEUTICALS INC.
$48
Gilead Sciences, Inc.
$37
Kyowa Kirin, Inc.
$36
Alexion Pharmaceuticals, Inc.
$33
PharmaEssentia USA Corporation
$32
ADC Therapeutics America, Inc.
$31
Ipsen Biopharmaceuticals, Inc
$30
Puma Biotechnology, Inc.
$29
Exelixis Inc.
$27
Verastem, Inc.
$25
Emmaus Medical, Inc.
$24
EISAI INC.
$22
ABBVIE INC.
$22
Mirati Therapeutics, Inc.
$21
TOLMAR Pharmaceuticals, Inc.
$21
BeiGene USA, Inc.
$20
ARRAY BIOPHARMA INC
$19
AMAG Pharmaceuticals, Inc.
$19
Dendreon Pharmaceuticals LLC
$19
Merck Sharp & Dohme LLC
$18
MEDIVATION FIELD SOLUTIONS LLC
$18
Dova Pharmaceuticals
$18
Pharmacosmos Therapeutics Inc.
$18
Epizyme, Inc.,
$17
EMD Serono, Inc.
$17
G1 Therapeutics, Inc.
$16
Sobi, Inc
$16
Clovis Oncology, Inc.
$16
Takeda Pharmaceuticals U.S.A., Inc.
$14
SECURA BIO, INC.
$13
GE HealthCare
$13
Servier Pharmaceuticals LLC
$12
Eisai Inc.
$12
Top 3 companies account for 27.1% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · Abraxane · Alecensa · Avastin · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CALQUENCE · COPIKTRA · COSELA · CYRAMZA · Cabometyx · Copiktra · Cresemba · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · Endari · Enhertu · Erleada · FERAHEME · FOUNDATIONONE · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Inrebic · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LUMAKRAS · LUMOXITI · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONUREG · OPDIVO · ORGOVYX · OXBRYTA · PADCEV · PEMAZYRE · PIQRAY · POLIVY · POTELIGEO · PROMACTA · PROVENGE · Pomalyst · REBLOZYL · RYBREVANT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SUTENT · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · ULTOMIRIS · VENCLEXTA · VOTRIENT · Vitrakvi · WELIREG · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · YONSA · ZEJULA · ZEPZELCA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $4 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
10
Per 100K population
1.6
County median income
$75,817
Nearest hospital
VIERA HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Dalal is a mixed practice specialist, with above-average Medicare volume (top 15% in FL), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Dalal experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Dalal performed 39,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Dalal receive payments from pharmaceutical companies?
Yes. Dr. Dalal received a total of $9,327 from 65 companies across 556 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Dalal's costs compare to other hematologys in Melbourne?
Dr. Dalal's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Dalal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Melbourne
Browse hematologys in Melbourne ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology